Why I’m avoiding these 3 FTSE 100 stocks in 2020

G A Chester sees different issues with these three FTSE 100 (INDEXFTSE:UKX) stocks, but valuations are the acid test.

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

There are a number of FTSE 100 stocks I think could disappoint investors in 2020. Among them are AstraZeneca (LSE: AZN), St. James’s Place (LSE: STJ) and Scottish Mortgage Investment Trust (LSE: SMT). Here’s why I’m avoiding these three.

Dubious core strength

AstraZeneca’s management has maintained the core earnings per share (EPS) guidance it gave at the start of the year of $3.50-$3.70 for 2019. At the midpoint and current exchange rates, this gives a price-to-earnings (P/E) ratio of 26.5 at a share price of 7,300p.

This is a huge premium to Footsie pharma peers GlaxoSmithKline and Hikma Pharmaceuticals, which trade at P/Es of 14.4 and 17.7 respectively. Furthermore, I’d argue AZN’s core EPS, on which the 26.5 P/E is based, grossly overstates its real core earnings, and that the true P/E is nearer a jaw-dropping 40.

This is because I exclude one-off profits from the divestment of non-core assets, which can’t go on forever but which AZN books as core operating profit. I also include legal costs (a routine expense in operating a big pharma company), which AZN excludes. AZN looks overvalued to me on its own core EPS measure, but grossly overvalued on what I consider its true core earnings.

Iffy business model

I’m avoiding wealth manager St. James’s Place on a view that it’s not only overvalued, but also has an iffy business model, and will have to change, with profit-margin-sapping consequences.

At a share price of around 1,100p, STJ’s P/E is 32.4 on forecast EPS of 34p for 2019. This earnings multiple is far too high, in my opinion. Furthermore, a valuation of more than 3% of funds under management (FUM) has proved a trusty indicator of overvaluation, in my experience. With a market capitalisation of £5.88bn, and FUM of £112.82bn, STJ is valued at 5.2% of FUM.

The company’s management fees and exit fees are excessive, in my view. Investors haven’t worried too much about this, seeing their portfolios increase in value over the last 10 years of rising markets, but are likely to pay a lot more attention in a downturn. Furthermore, with investors generally becoming a lot savvier about the corrosive effect of fees on returns, I think STJ will ultimately have to reset its margins.

Bonkers

It’s a peculiar and persistent feature of the UK stock market that some investment trust or another will rise from the FTSE 250 to the FTSE 100. However, no trust in history has gained sufficient critical mass to maintain its position in the top index.

Scottish Mortgage is the current representative in the FTSE 100. It’s achieved its status by a combination of high returns (471% over the last 10 years) and increasing popularity with investors (taking its shares to a premium to net asset value (NAV)).

The company has surfed on the outperformance of the US market and tech sector, holding a number of the so-called FAANG stocks, and the likes of Illumina and Tesla. The managers of the trust have borrowed money to gear returns (gearing is currently 9%), and remain optimistic on the outlook.

Personally, I think the valuations of many of the underlying holdings are bonkers. I fear a de-rating, SMT’s NAV dropping, gearing working negatively, and the shares moving to a wide discount to NAV. If so, SMT will become another in the long history of investment trusts failing to maintain a place in the FTSE 100.

G A Chester has no position in any of the shares mentioned. The Motley Fool UK owns shares of and has recommended GlaxoSmithKline and Tesla. The Motley Fool UK has recommended AstraZeneca and Hikma Pharmaceuticals. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Businessman hand stacking money coins with virtual percentage icons
Investing Articles

£5,000 invested in Tesco shares 5 years ago is now worth this much…

Tesco share price growth has been just part of the total profit picture, but can our biggest supermarket handle the…

Read more »

Investing Articles

Here’s why I’m bullish on the FTSE 100 for 2026

There's every chance the FTSE 100 will set new record highs next year. In this article, our Foolish author takes…

Read more »

Thoughtful man using his phone while riding on a train and looking through the window
Growth Shares

UK interest rates fall again! Here’s why the Barclays share price could struggle

Jon Smith explains why the Bank of England's latest move today could spell trouble for the Barclays share price over…

Read more »

Man hanging in the balance over a log at seaside in Scotland
Investing Articles

2 out-of-favour FTSE 250 stocks set for a potential turnaround in 2026

These famous retail stocks from the FTSE 250 index have crashed in 2025. Here's why 2026 might turn out to…

Read more »

Young female business analyst looking at a graph chart while working from home
Investing Articles

Down over 30% this year, could these 3 UK shares bounce back in 2026?

Christopher Ruane digs into a trio of UK shares that have performed poorly this year in search of possible bargains…

Read more »

Mature people enjoying time together during road trip
Investing Articles

Yields up to 8.5%! Should I buy even more Legal & General, M&G and Phoenix shares?

Harvey Jones is getting a brilliant rate of dividend income from his Phoenix shares, and a surprising amount of capital…

Read more »

Light trails from traffic moving down The Mound in central Edinburgh, Scotland during December
Investing Articles

Up 7.5% in a week but with P/Es below 8! Are JD Sports Fashion and easyJet shares ready to take off?

easyJet shares have laboured in 2025, but suddenly they're flying. The same goes for JD Sports Fashion. Both still look…

Read more »

US Stock

I think this could be the best no-brainer S&P 500 purchase to consider for 2026

Jon Smith reveals a stock from the S&P 500 that he feels has the biggest potential to outperform the index,…

Read more »